Skip to main content
. 2021 Dec 9:kqab164. doi: 10.1093/occmed/kqab164

Table 2.

Prevalence of SARS-CoV-2 antibodies in first responders and association with seropositivity

Total number of participants Rate of seropositive participants OR for being
seropositive
unadjusted
AORa for being
seropositive
Total number of participants without prior self-reported SARS-CoV-2 infection (positive by PCR)b Distribution among seropositive participants, but without prior self-reported SARS-CoV-2 infection (positive by PCR)b
n (column-%) n (row-%c) [95% CI] OR [95% CI] AOR [95% CI] n (column-%) n (row-%c) [95% CI]
Total 745 (100) 34 (4) [3.1–6.2] 723 (100) 20 (3) [1.6–4.1]
Sex
 Male 682 (92) 33 (5) [3.3–6.6] Ref.d Ref. 660 (91) 19 (2) [1.0–3.9]
 Female 62 (8) 1 (1) [0.1–8.4] 0.29 [0.0–2.9] 0.22 [0.0–2.2] 62 (9) 1 (2) [1.0–8.7]
Missing 1 (0) 1 (0) 0 (0)
Age group
 18–39 years 375 (51) 21 (5) [3.5–8.3] Ref. Ref. 361 (40) 12 (3) [1.7–5.6]
 40 years and older 355 (49) 12 (3) [1.7–5.6] 0.57 [0.3–1.2] 0.53 [0.3–1.2] 347 (47) 7 (2) [0.8–3.9]
Missing 15 (2) 1 (7) [0.1–29.8] 15 (3) 1 (7) [0.1–29.8]
Household size
 One person 120 (16) 9 (7) [3.8–13.5] Ref. Ref. 116 (16) 7 (6) [2.8–11.8]
 Two persons 254 (34) 10 (4) [2.0–6.9] 0.49 [0.2–1.3] 0.54 [0.2–1.4] 246 (34) 3 (1) [3.2–11.4]
 Three or more persons 369 (450) 15 (4) [2.3–6.4] 0.51 [0.2–1.2] 0.52 [0.2–1.3] 359 (50) 10 (3) [1.3–4.9]
Missing 2 (0) 2 (0) 0 (0)
Level of education
 Lower/middle 383 (51) 16 (4) [2.6–6.8] Ref. Ref. 369 (51) 7 (2) [0.7–3.7]
 Higher 348 (47) 18 (5) [2.9–7.5] 1.02 (0.5–2.0) 0.86 [0.4–1.8] 340 (47) 13 (4) [2.1–6.3]
 Other/still a student 9 (1) 0 (0) 9 (1) 0 (0)
Missing 5 (1) 0 (0) 5 (1) 0 (0)
Work taske
 Firefighters 540 (78) 26 (5) [3.1–6.8] 1.97 [0.6–6.2] 1.80 [0.5–3.9] 525 (73) 14 (3) [1.4–4.3]
 Paramedics: emergency rescue 400 (60) 24 (6) [3.4–8.6] 2.52 [1.0–6.3] 2.45 [0.8–7.5] 386 (53) 14 (3) [1.9–5.8]
 Paramedics: patient transport 162 (24) 9 (5) [2.8–10.1] 1.52 [0.6–3.5] 1.39 [0.6–3.3] 158 (22) 7 (4) [2.0–8.7]
 Technicians administrative official 108 (17) 2 (2) [0.3–6.3] 0.35 [0.1–1.8] 0.44 [0.1–2.3] 107 (15) 2 (2) [0.3–6.3]
Chronic condition
 No 620 (83) 29 (5) [3.1–6.5] Ref. Ref. 605 (84) 18 (3) [1.7–4.5]
 Yes 121 (16) 5 (4) [1.6–9.2] 0.87 [0.3–2.4] 1.22 [0.4–3.5] 115 (16) 2 (2) [0.3–6.0]
Missing 0 (0) 3 (0)
PCR test since February 2020
 Yes 260 (35) 20 (8) [4.9–11.5] Ref. Ref. 240 (33) 6 (2) [1.0–5.2]
 No, no test needed 394 (53) 12 (3) [1.6–5.1] 0.36 [0.2–0.8] 0.35 [0.2–0.8] 394 (55) 12 (3) [1.6–5.1]
 No, but I thought about getting tested and I asked for one, but did not get one 89 (12) 2 (2) [0.4–7.7] 0.26 [0.0–1.5] 0.27 [0.0–1.3] 89 (12) 2 (2) [0.4–7.7]
Missing 2 (0) 0 (0) 0 (0) 0 (0)
Self-reported COVID-19
 Negative 236 (32) 6 (2) [1.0–5.3] Ref. Ref.
 Positive 20 (3) 14 (70) [48.2–85.8] 21.73 [6.7–68.7] 18.54 [6.0–57.6]
 I don’t know 3 (0) 0 (0)
Symptoms since February 2020f
 Fever ≥38°C 80 (11) 6 (7) [3.3–15.3] 1.86 [0.9–4.8] 1.78 [0.7–4.6] 77 (11) 4 (5) [1.8–12.5]
 Cough 222 (30) 16 (7) [4.3–11.3] 2.23 [1.1–4.6] 2.27 [1.1–4.8] 212 (30) 8 (4) [1.7–7.1]
 Pneumonia 6 (1) 1 (17) [0.7–56.5] 4.39 [0.5–39.7] 4.29 [0.5–39.1] 5 (1) 0 (0)
 Dyspnea or shortness of breath 32 (4) 6 (19) [8.7–35.4] 5.85 [2.2–15.6] 7.67 [2.7–20.4] 25 (4) 0 (0)
 Pain when breathing 21 (3) 1 (5) [0.0–22.6] 1.04 [0.1–8.7] 1.02 [0.1–8.5] 20 (3) 0 (0)
 Congested nose 283 (38) 20 (7) [4.4–10.5] 2.50 [1.2–5.2] 2.58 [1.2–5.5] 274 (38) 12 (4) [2.3–7.3]
 Sore throat 255 (35) 16 (6) [4.2–11.1] 1.78 [0.9–3.6] 1.77 [0.8–3.7] 244 (34) 8 (3) [1.5–6.2]
 Loss of smell 23 (3) 12 (52) [33.0–71.1] 36.9 [14.4–94.6] 45.6 [16.4–127.3] 11 (2) 1 (9) [0.3–37.8]
 Loss of taste 18 (2) 8 (45) [24.5–66.5] 22.7 [8.1–63.3] 24.1 [8.3–69.8] 10 (1) 1 (10) [0.3–40.5]
 No symptoms 252 (34) 2 (1) [0.0–2.7] 0.09 [0.0–0.6] 0.03 [0.0–1.9] 248 (34) 1 (0) [0.0–2.1]
Contact to a confirmed COVID-19 case
 No 387 (52) 9 (2) [1.0–4.2] Ref. Ref. 384 (53) 8 (2) [0.9–3.9]
 Yes, with a distance ≥1.5m 121 (16) 3 (2) [0.7–6.9] 1.85 [0.7–4.8] 1.84 [0.7–4.7] 119 (17) 2 (2) [0.3–5.8]
 Yes, with a distance <1.5m 234 (31) 21 (9) [5.8–13.2] 7.3 [4.3–12.4] 7.5 [4.3–12.8] 219 (30) 10 (4) [2.3–8.1]
Missing 3 (0) 1 (33) [1.5–75.6] 1 (0.1) 0 (0)
Other exposure
 Working with patients 398 (54) 22 (5) [3.5–8.1] 1.66 [0.8–3.5] 1.51 [0.7–3.8] 382 (53) 12 (3) [1.6–5.2]
 Working with customers 123 (17) 3 (2) [0.6–6.8] 1.28 [0.7–2.4] 1.36 [0.8–2.4] 109 (15) 1 (1) [−0.2 to 4.4]
 Attended an event with ≥50 persons 253 (34) 16 (6) [3.8–9.9] 1.78 [0.9–3.7] 1.65 [0.8–3.5] 246 (34) 10 (4) [2.0–7.2]
 Travelled outside the EU 43 (6) 2 (5) [1.1–15.4] 1.01 [0.2–4.7] 0.95 [0.2–4.3] 41 (6) 0 (0)
 Travelled within the EU 268 (36) 15 (5) [3.2–8.9] 1.44 [0.7–3.0] 1.59 [0.8–3.3] 258 (36) 7 (3) [1.1–5.3]
Adherence to public health measures
 Adheres completely 438 (59) 22 (5) [3.2–7.3] Ref. Ref. 420 (58) 10 (2) [1.1–4.2]
 Adheres partly 300 (40) 11 (4) [1.9–6.3] 1.85 [0.7–4.8] 1.84 [0.7–4.7] 297 (41) 9 (3) [1.4–5.5]
Missing 7 (1) 1 (14) [0.5–51.5] 7.31 [4.3–12.4] 7.52 [4.3–12.8] 6 (1) 1 (17) [0.7–56.5]

aAOR = adjusted odds ratio for age and sex.

bFor the analysis of subjects with antibodies but without self-reported SARS-CoV-2 infection, all subjects with positive PCR test (n = 20) or unknown PCR result (n = 2) were excluded. Therefore, the sample size for this group was 723 individuals.

cThis is the test-adjusted seroprevalence.

dref = reference group.

eOne person could work in more than one field.

fMultiple choices possible.